Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504. Gillison, M. L., Ferris, R. L., Harris, J., Colevas, A., Mell, L. K., Kong, C., Jordan, R. C., Moore, K., Minh Tam Truong, Kirsch, C., Clump, D., Ohr, J., He, K., Blakaj, D., Deeken, J. F., Machtay, M., Curran, W., Quynh-Thu Le AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.15_suppl.6073
View details for Web of Science ID 000487345806038